Treatment of chronic post-viral hepatitis C

Chronic post-viral hepatitis C is a major public health problem, with around 71 million people infected worldwide. Until 2011, treatment was based on pegylated dual therapy, with a sustained virological response (SVR) rate of between 40% and 80%, depending on the genotype, albeit with a number of contraindications and adverse effects limiting its prescription. The advent of new direct antiviral agents (DAAs) has brought about a metamorphosis in the management of chronic post-viral hepatitis C, with SVR reaching 90-100% and few adverse effects. The aim of our work was to evaluate the efficacy and safety of direct antiviral agents in a cohort of patients with chronic post-viral hepatitis C. This was a descriptive, cross-sectional, prospective study including all patients followed for chronic post-viral hepatitis C in the Nabeul hepato gastroenterology department, and who were included in the national hepatitis C virus eradication program.

Autorentext

Dr Asma ben Mohamed gastro-entérologue exerçant dans le secteur public en Tunisie et enseignante à la faculté de médecine de Tunis. Passionnée par la recherche, les travaux scientifiques ainsi que la pédagogie.